What is ARDX stock price today?

ARDX (Ardelyx Inc) stock is trading at $6.04 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ARDX stock going up or down today?

ARDX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ARDX stock now?

The decision to buy ARDX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ARDX a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ARDX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ARDX stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ARDX is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ARDX's P/E ratio?

P/E ratio data for ARDX will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ARDX's market cap?

ARDX (Ardelyx Inc) has a market capitalization of $1.52 billion, making it a small-cap stock.

What is ARDX's price to book ratio?

ARDX trades at a price-to-book (P/B) ratio of 10.23, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ARDX pay dividends?

ARDX does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ARDX's dividend yield?

ARDX does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ARDX stock a good long-term investment?

ARDX's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ARDX's revenue growth rate?

ARDX has shown revenue growth of 0.3% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

ARDX is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in ARDX?

Key risks for ARDX include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ARDX compare to its competitors?

Compare ARDX to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ARDX's performance and positioning.

What is ARDX's stock price target for 2026?

Our AI model provides price targets for ARDX based on fundamental analysis: Bull case $7.85 (+30%), Base case $6.95 (+15%), Bear case $5.44 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ARDX?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ARDX. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ARDX's next earnings report?

ARDX reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ARDX - Ardelyx Inc

NYSE * Health Care * Biotechnology

$6.04

$-0.21 (-3.36%)

About Ardelyx Inc

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

ARDX Key Statistics

Market Cap

$1.52B

P/B Ratio

10.23

EPS

$-0.24

Revenue Growth

+0.3%

Profit Margin

-0.1%

Employees

489

How ARDX Compares to Peers

ARDX has the fastest revenue growth among competitors

ARDX is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ARDX(This stock)	$1.52B	N/A	0%	-0.1%	-
AMGNAmgen Inc	$181.37B	23.4	0%	0.2%	vs AMGN
GILDGilead Sciences	$165.99B	18.2	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$110.97B	26.0	0%	0.4%	vs VRTX
REGNRegeneron Pharmaceuticals	$65.81B	15.3	0%	0.3%	vs REGN
BIIBBiogen Inc	$29.08B	21.2	0%	0.1%	vs BIIB

Ardelyx Inc Company Information

Headquarters: California; U.S.A
Website: www.ardelyx.com
Sector: Health Care
Industry: Biotechnology

ARDX - Ardelyx Inc

About Ardelyx Inc

ARDX Key Statistics

How ARDX Compares to Peers

Ardelyx Inc Company Information

ARDX Lician Score

ARDX Financial Snowflake

Upcoming Events for ARDX